°Ç°º¸Çè½É»çÆò°¡¿ø(¿øÀå °À±±¸) ½É»çÆò°¡¿¬±¸¼Ò(¼ÒÀå ±èÀ±)´Â ¿À´Â 19ÀÏ ¿ÀÈÄ 2½Ã 30ºÐ¿¡ º»¿ø ÁöÇÏ 1Ãþ ´ë°´ç¿¡¼ 'Á¦27ȸ ½ÉÆòÆ÷·³'À» °³ÃÖÇÑ´Ù.
À̹ø ½ÉÆòÆ÷·³Àº ‘ÀÇ·á±â¼ú ±Þ¿©°áÁ¤¿¡ ´ëÇÑ ¿Ü±¹ÀÇ °æÇè°ú ±³ÈÆ(Coverage Decision Making in Health Technology Assessment : Experiences and Lessons of Foreign Countries)’À» ÁÖÁ¦·Î ¿Ü±¹ ¿¬ÀÚÀÇ ÁÖÁ¦¹ßÇ¥ ¹× ÁúÀÇÀÀ´ä Çü½ÄÀ¸·Î ÁøÇàµÈ´Ù.
ù ¹ø° ¹ßÇ¥´Â ¿µ±¹ NICEÀÇ ·Õ¼ÕÀÌ ‘ÀÇ·á±â¼ú ±Þ¿©°áÁ¤¿¡ ´ëÇÑ ¿µ±¹ NICEÀÇ °æÇè°ú ±³ÈÆ(Using health technology assessment in coverage decision making: experiences and lessons from NICE)’À» ¹ßÇ¥ÇÑ´Ù.
ÀÌ¾î µÎ ¹ø°·Î´Â ÀϺ» ±¹¸³º¸°ÇÀÇ·á°úÇпø ÈÄÄí´Ù°¡ ‘ÀϺ»ÀÇ ÀǾàÇ° °¡°Ý°áÁ¤ ¹× ÀÇ·á±â¼úÆò°¡(Drug Pricing and HTA in Japan)’¸¦ ¹ßÇ¥ÇÑ´Ù.
¸¶Áö¸·À¸·Î ¿µ±¹ÀÇ °íµå¸¸ÀÌ ‘ó¹æ È¿À²¼º °³¼±¿¡ ´ëÇÑ À¯·´ÀÇ °æÇè°ú ½Ã»çÁ¡(Initiatives across Europe to enhance prescribing efficiency to maintain universal coverage: findings and implications)’¿¡ ´ëÇØ ¹ßÇ¥ÇÒ ¿¹Á¤ÀÌ´Ù.
½ÉÆòÆ÷·³Àº º¸°ÇÁ¤Ã¥Çö¾È µî¿¡ ´ëÇÏ¿© ÀÇ»ç¼ÒÅëÀÇ ÀåÀ» ¸¶·ÃÇϴµ¥ ÀÇÀǸ¦ µÎ°í ÀÖ´Ù. °ü½É ÀÖ´Â ¿¬±¸ÀÚµé°ú Âü¿©¸¦ Èñ¸ÁÇÏ´Â Çлý ¹× ÀϹÝÀÎÀº ´©±¸µçÁö Âü¿©ÇÒ ¼ö ÀÖÀ¸¸ç, º°µµÀÇ µî·ÏÀýÂ÷³ª ºñ¿ëÀº ¾ø´Ù. < ÀúÀÛ±ÇÀÚ © ¾à±¹½Å¹® ¹«´ÜÀüÀç ¹× Àç¹èÆ÷±ÝÁö > |